WEBULL
News
VNRX
0.2500
-0.79%
-0.0020
Weekly Report: what happened at VNRX last week (1215-1219)?
Weekly Report · 5d ago
VolitionRX Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/18 12:33
VolitionRX Price Target Cut to $3.00/Share From $5.00 by D. Boral Capital
Dow Jones · 12/18 12:33
D. Boral Capital Maintains Buy on VolitionRX, Lowers Price Target to $3
Benzinga · 12/18 12:23
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 12/17 17:06
VolitionRx Issues 2025 Business Review
Benzinga · 12/17 13:46
Weekly Report: what happened at VNRX last week (1208-1212)?
Weekly Report · 12/15 09:22
VolitionRX Announces CEO Departure Amid Cost Realignment
TipRanks · 12/11 22:29
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment
TipRanks · 12/11 14:15
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
PR Newswire · 12/11 14:00
Weekly Report: what happened at VNRX last week (1201-1205)?
Weekly Report · 12/08 09:22
VolitionRX Gains Momentum with Strategic Advancements in Sepsis and Cancer Diagnostics
TipRanks · 12/05 17:25
VolitionRX Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/04 18:15
VolitionRX Price Target Maintained With a $5.00/Share by D. Boral Capital
Dow Jones · 12/04 18:15
D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target
Benzinga · 12/04 18:05
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
PR Newswire · 12/04 14:00
VolitionRX Cut to Hold From Buy by Maxim Group
Dow Jones · 12/03 19:19
Maxim Group Downgrades VolitionRX to Hold
Benzinga · 12/03 19:09
VolitionRx downgraded to Hold from Buy at Maxim
TipRanks · 12/03 13:00
Weekly Report: what happened at VNRX last week (1124-1128)?
Weekly Report · 12/01 09:21
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.